

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Angell et al.	27 August 2008
Serial No.:	10/522,955	Group Art Unit: 1626
Filed:	14 November 2005	Examiner: M. Barker
For:	Fused Heteroaryl Derivatives for Use As p38 Kinase Inhibitors	

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

FILING OF A FIRST INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(c)

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein should not, however, be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited document is enclosed, except for the US patents and publications.

The documents cited herein are listed on the enclosed PTO Form 1449. A copy of each cited document is enclosed, except U.S. Patent documents, and those references which are already part of the file wrapper. This information disclosure statement is being filed under the provisions of 37 C.F.R. §1.97(c)(2), i.e., *after* three months of the filing date of the subject application or after the mailing date of the first Office Action on the merits, whichever event occurred last but *before* the mailing date of either a Final Action under 37 CFR §1.113 or a Notice of Allowance under 37 CFR §1.311, along with authorization to charge the \$180.00 fee specified in 37 C.F.R. §1.17(p) to the Deposit Account No. 19-2570.


This supplemental information disclosure statement provides for an updated listing of Applicants copending related applications. Pursuant to a request by the PTO in a related application, the respective US serial numbers for Applicants co-pending applications are now cited on the accompanying PTO 1449 form. The Examiners attention is drawn to the following listing of copending related applications, as shown below, in tabular form.

Foreign Patent	Corresponding US Patent
WO 03/032980	US 7,396,943
WO 03/033483	US 7,151,118 US 7,309,800
WO 03/032987	US 7,166,623 US 2007/0112046
WO 03/033457	US 7,183,297 US 2007/0142476
WO 03/032986	US 7,384,963
WO 05/014550	US 2007/0161684
WO 04/089875	US 2007/0105850
WO 04/089874	US 2007/0129354
WO 03/093248	US 2006/0089393
WO 03/032970	USSN 10/492,714 Filed 15 Apr 04 Angell, et al.

Foreign Patent	Corresponding US Patent
WO 03/033482	US 2005/0065195
WO 03/068747	US 7,125,898 US 2006/0264479 US 2006/0276516
WO 03/032971	US 2004/0242868
WO 03/032972	US 7,208,629
WO 04/089876	US 7,271,289
WO 05/073219	US 2007/0142372
WO 06/110173	US 2008/0051416
WO 05/073217	US 2007/0054942
WO 05/073232	US 2007/0161673
WO 06/134382	USSN 11/917,534 Filed 16 June 2006 Chandi, et al.
WO 05/073189	USSN 10/587,790 Filed 27 Jan 05 Bamborough, et al.

Should the Examiner have any questions or wish to discuss any aspect of this case, the Examiner is encouraged to call the undersigned at the number below. If any additional fees or charges are required by this paper the Commissioner is hereby authorized to charge Deposit account 19-2570 accordingly.

Respectfully submitted,



Dara L. Dinner  
Attorney for Applicants  
Registration No. 33,680

GLAXOSMITHKLINE  
Corporate Intellectual Property-UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone: (610) 270-5017 Facsimile: (610) 270-5090